Patient selection biomarkers for CDK7 inhibitor samuraciclib (SAM; CT7001) combined with selective estrogen receptor degrader (SERD) in hormone receptor-positive advanced breast cancer (HR+ ABC) post-CDK4/6 inhibitor (CDK4/6i)

giredestrant (GDC-9545) - Roche

samuraciclib (CT7001) - Carrick Therap

fulvestrant - Generic mfg.

https://cslide.ctimeetingtech.com/coasis_21219/attendee/confcal_1/presentation

Mafalda Oliveira; Begoña Bermejo; Einav Gal-Yam; Maria Gion Cortes; Sara A. Hurvitz; Seock-Ah Im; Kyung H. Jung; Cristina Saavedra Serrano; Saeed Sadeghi; Amir Sonnenblick; Seth Wander; Stuart Mcintosh; R. Charles Coombes; Hope S. Rugo

Mar 30, 2025